|
Published by: Global Markets Direct
Published: Sep. 25, 2012 - 137 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Herpes Simplex Infections Overview
- Therapeutics Development
- An Overview of Pipeline Products for Herpes Simplex Infections
- Herpes Simplex Infections Therapeutics under Development by Companies
- Herpes Simplex Infections Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Herpes Simplex Infections Therapeutics – Products under Development by Companies
- Herpes Simplex Infections Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Herpes Simplex Infections Therapeutics Development
- Vical Incorporated
- Antigenics, Inc.
- GenVec, Inc.
- Novartis AG
- CEL-SCI Corporation
- Mymetics Corporation
- NanoViricides, Inc.
- Nutra Pharma Corporation
- Peregrine Pharmaceuticals, Inc.
- CytoGenix, Inc.
- Alnylam Pharmaceuticals, Inc
- Flamel Technologies S.A.
- Starpharma Holdings Limited
- Summit Corporation plc
- BioAlliance Pharma SA
- Oryzon
- Functional Genetics, Inc.
- Colby Pharmaceutical Company
- Osel Inc.
- AiCuris GmbH & Co. KG
- Asahi Kasei Pharma
- AlphaVax, Inc.
- Nitric Biotherapeutics, Inc.
- Romark Laboratories, L.C.
- Chimerix, Inc.
- Lumavita AG
- NanoBio Corporation
- PharmaNova Inc.
- Immune Design Inc.
- Redox Pharmaceutical Corporation
- PepTcell Limited
- Genocea Biosciences, Inc.
- Beech Tree Labs, Inc.
- EMS S.A.
- Herpes Simplex Infections – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- tenofovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- acyclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RPI-78M - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RPI-MN - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- famciclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- simplivir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CEL-1000 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- doxorubicin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HSV Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NB-001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LMV-601 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HSV-2 Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HSV-2 Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HerpV Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AIC-316 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- acyclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- valacyclovir hydrochloride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SPL-7013 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- acyclovir CR - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- valacyclovir hydrochloride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RNAi Therapeutic For HSV Infection - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BTL-TML-HSV - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- acyclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Antiviral Program - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MucoCept Platform - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GEN-003 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HSV-2 Px - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- penciclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- famciclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- famciclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- JVRS-100 + HSV-2 Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- New Thiazolides - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug For Herpes Simplex - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PGN-632 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ID-G103 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PN 200 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LSD1 Inhibitor For HSV - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PN 201 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valacyclovir - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HSV Program - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HerpeCide-I - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Herpes Simplex Infections Therapeutics – Drug Profile Updates
- Herpes Simplex Infections Therapeutics – Discontinued Products
- Herpes Simplex Infections Therapeutics - Dormant Products
- Herpes Simplex Infections – Product Development Milestones
- Featured News & Press Releases
- Aug 15, 2012: Genocea Initiates Phase I/IIa Study With Therapeutic Vaccine Candidate For Herpes Simplex Virus-2 Infection
- Aug 07, 2012: AiCuris To Present Data On AIC316 At International Herpesvirus Workshop
- Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig
- May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier
- May 22, 2012: Vical Publishes Preclinical Results Of Herpes Simplex Vaccine In Journal Of General Virology
- May 16, 2012: Vical Presents Update On Herpes Simplex Vaccine Development At ASGCT Conference
- May 04, 2012: Genocea Highlights Key Progress In Development Of First Vaccine Candidate, Targeting HSV-2
- Apr 16, 2012: AiCuris To Report AIC316 Phase II trial Data At International Meetings
- Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure
- Oct 03, 2011: Vical Reports Prophylactic And Therapeutic Efficacy With Herpes Simplex Vaccines In Guinea Pig Model
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Herpes Simplex Infections, H2 2012
- Products under Development for Herpes Simplex Infections – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Vical Incorporated, H2 2012
- Antigenics, Inc., H2 2012
- GenVec, Inc., H2 2012
- Novartis AG, H2 2012
- CEL-SCI Corporation, H2 2012
- Mymetics Corporation, H2 2012
- NanoViricides, Inc., H2 2012
- Nutra Pharma Corporation, H2 2012
- Peregrine Pharmaceuticals, Inc., H2 2012
- CytoGenix, Inc., H2 2012
- Alnylam Pharmaceuticals, Inc, H2 2012
- Flamel Technologies S.A., H2 2012
- Starpharma Holdings Limited, H2 2012
- Summit Corporation plc, H2 2012
- BioAlliance Pharma SA, H2 2012
- Oryzon, H2 2012
- Functional Genetics, Inc., H2 2012
- Colby Pharmaceutical Company, H2 2012
- Osel Inc., H2 2012
- AiCuris GmbH & Co. KG, H2 2012
- Asahi Kasei Pharma, H2 2012
- AlphaVax, Inc., H2 2012
- Nitric Biotherapeutics, Inc., H2 2012
- Romark Laboratories, L.C., H2 2012
- Chimerix, Inc., H2 2012
- Lumavita AG, H2 2012
- NanoBio Corporation, H2 2012
- PharmaNova Inc., H2 2012
- Immune Design Inc., H2 2012
- Redox Pharmaceutical Corporation, H2 2012
- PepTcell Limited, H2 2012
- Genocea Biosciences, Inc., H2 2012
- Beech Tree Labs, Inc., H2 2012
- EMS S.A., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Herpes Simplex Infections Therapeutics – Drug Profile Updates
- Herpes Simplex Infections Therapeutics – Discontinued Products
- Herpes Simplex Infections Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Herpes Simplex Infections, H2 2012
- Products under Development for Herpes Simplex Infections – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHerpes Simplex Infections – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Herpes Simplex Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Simplex Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections. Herpes Simplex Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Herpes Simplex Infections.
- A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Simplex Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
